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Ratio: Asthma is a major public health problem, with bronchial inflammation as the thera-
peutic target. The role of dietary fish oil derived polyunsaturated fatty acids (PUFAs) in allergic
inflammation is controversial. Most asthmatics suffer from mild disease and non-pharmacologic
interventions are attractive. This study investigates the anti-inflammatory potential of nutri-
tional PUFAs in an experimentally induced bronchial inflammation.
Methods: We examined 38 grass pollen allergic asthmatics and 19 controls. History of dietary
PUFA intake was compared with levels of PUFAs in erythrocyte membranes, and stratified ac-
cording to low (25th quartile; Q25) and high (75th quartile; Q75) ratios of omega-3 (n-3) to
omega-6 (n-6) PUFAs as a surrogate for anti-inflammatory (Q75) or proinflammatory (Q25)
effects. Bronchial inflammation was simulated with one-step inhalation of grass pollen. Bron-
chial response (exhaled nitric monoxide, eNO as surrogate for inflammation, decrease of FEV1)
was correlated with levels of PUFAs in erythrocyte membranes.
Results: Ratios of n-3/n-6 PUFA were significantly lower in asthmatics than in healthy controls.
Levels of eNO were significantly higher in Q25 asthmatics than in Q75 asthmatics (pZ 0.040).
There was a trend of higher bronchial hyperreactivity in Q25 asthmatics (median PD20 0.27 vs.
0.14; n.s.), induced by specific bronchial challenge with grass pollen (FEV1 decrease 16.7 vs.
23.1%; n.s.).ospital, J.W. Goethe University, Theodor Stern Kai 7, D-60590 Frankfurt, Germany. Tel.: þ49 69 6301
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1794 R. Kitz et al.Conclusion: When stratifying for erythrocyte membrane PUFA content as a surrogate for
alimentary intake, we found mild effects on bronchial allergic inflammation. Future interven-
tion studies with pharmacological PUFA doses appear suitable to clarify dietary PUFA role as an
adjunctive intervention to the established treatment of asthma.
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The prevalence of asthma continues to increase despite
improved treatment options. There is accumulating
evidence that dietary modifications have the potential to
influence the severity of asthma and reduce the dose
requirements of drug treatment. Possibly contributing to the
increasing incidence of asthma in industrialized societies
may be the consumption of a proinflammatory diet. In the
typical Western diet, omega (n)-6 polyunsaturated fatty
acids (PUFAs) dominate, resulting in the release of proin-
flammatory arachidonic acid-derived metabolites. Consid-
erable interest in the possible value of polyunsaturated fatty
acids (PUFAs) was sparked by ecological studies showing
beneficial associations between intake of oily fish rich in n-3
fatty acids, and allergic airway diseases.1e4 Additional
impetus for research came from observations that n-3 fatty
acids might have a protective or even therapeutic effect.
This may be attributable to their impact on mediators of
inflammation thought to be related to the pathogenesis of
asthma.5,6 The dietary intake of fatty acids affects the
production of eicosanoids, which are potent immune medi-
ators being mainly synthesized from eicosapentaenoic acid
(EPA; C20:5 n-3) and arachidonic acid (AA; C20:4 n-6). As
a correlate of a dysregulated Th2 response in atopic disease,
eicosanoids may interfere with immune cells shifting the
pattern of the cytokine production from Th1 to Th2. Since
EPA and other n-3 PUFAs seem to have the potential to
antagonize the effects of AA, a high dietary input of EPAmay
beassociatedwith adecreasing risk of allergic asthma. In this
context, the ratio of n-6/n-3 PUFA appears as a predictive
marker. Docosahexaenoic acid (DHA) and EPA are n-3 PUFAs
mainly derived from fish oils that competitively inhibit n-6
PUFA arachidonic acid metabolism, thus reducing the
generation of inflammatory leukotrienes and prostaglandins
as much as the production of cytokines from inflammatory
cells.7,8 In those studies, a fish oil diet improved pulmonary
function, with a concurrent reduction in asthma medication
use. Induced-sputum differential cell counts and concen-
trations of LTC4-LTE4, PGD2, IL-1beta, and TNF-alpha were
significantly reduced on the fish oil diet, supporting the
presumed anti-inflammatory effects.
Nevertheless, the efficacy of fish oil supplementation in
asthma has been a matter of debate.9 A recent cross
sectional study found that plasma n-3 fatty acids were not
associated with a reduced risk of asthma or atopy among
young adults.10 In keeping with this observation, no clinical
improvement in asthmatic symptoms was detected in some
interventional studies.11,12 However, other studies on
patients suffering from bronchial asthma have demon-
strated a benefit of n-3 PUFA supplementation.13e15 The
inconsistency among study results may be attributableto the heterogeneity in definitions of the study populations
(e.g., age, gender, clinical picture of asthma including its
severity), and the type of intervention (e.g., amounts of oil
and omega-3 fatty acid contents). Only few data are
available on the effect of fish oil supplementation on an
experimentally induced allergic airway response in patients
with allergic diseases.16
It is well known that allergen exposure has a negative
impact on preexisting allergic asthma.17 This was demon-
strated by a stepwise increase of eosinophils in sputum and of
the levels of exhaled nitric oxide (eNO, a marker of bronchial
inflammation).18,19 In order to investigate the anti-inflam-
matory effect of fish oil supplementation, we used this
established model of a standardized allergen exposure.
In a preceding study on allergic asthmatics and following
dietary EPA supplementation, we detected a 30% reduction
of the eNO increase.20 Thus, we challenged patients
sensitized to grass pollen with a standardized dose of grass
pollen preseasonally and correlated it with their plasma
and erythrocyte PUFA contents. Our study is the first to
examine the impact of nutritional n-3 PUFAs on bronchial
inflammation and hyperreactivity in patients with preex-
isting allergic disease after single-dose allergen exposure.
Methods
Subjects and study design
Our studyexamined38grass pollenallergic asthmatics and19
age-matched healthy controls. Initially, each subject was
evaluated by a questionnaire referred to allergic and/or
asthmatic symptoms, skin prick test for common aero-
allergens including grass pollen, lung function, and meth-
acholine testing. Only subjects who were positive for grass
pollen as determined by positive skin prick test or specific IgE
and with an FEV1 and FVC 80% were challenged with grass
pollen extract on a separate visit day as explained later.
Controls were screened in the sameway frommedical school
students. Exclusion criteria were age <18 or >45 years,
regularly b2-agonist and/or inhaled corticosteroid or anti-
histamine usage, chronic disease conditions, pregnancy,
lactation, and the incapability to understand and follow
instructions.Written informed consentwas obtained fromall
participants. The study was approved by the local institu-
tional ethics committee and performed in accordance with
the declarations of Helsinki (1975) and Edinburgh (2000).
Lung function tests
Spirometry was performed with the MasterScreen
spirometer by Cardinal Health Inc., Hoechberg, Germany.
PUFAs and bronchial inflammation in allergic asthma 1795FEV1, FVC, PEF, and MEF25 were recorded as representative
lung function parameters. Peak flow measurements were
performed with the Mini-Wright peak flow meter
(60e800 L per min measuring range). The best of three
consecutive attempts was recorded by the participants on
a diary card.
Bronchial metacholine provocation test
To assess airway hyperreactivity, metacholine testing was
performed according to American Thoracic Society (ATS)
recommendations21 and was stopped when the FEV1
decreased at least 20% from individual baseline. PD20
metacholine was than calculated from the cumulative dose
resulting in a 20% fall of FEV1.
Allergen inhalation challenge protocol
Patients and controls were challenged with 150 mg of
purified aqueous allergen extract of grass pollen (5000 mg/
ml; Allergopharma Inc., Reinbek, Germany). The solutions
were delivered via a medic aid nebulizer and the aerosol
provocation system APS powered by compressed air
(Cardinal Health Inc., Hoechberg, Germany.).
Measurement of exhaled NO (eNO)
Measurements of eNO were done using the NIOX system
(Aerocrine Inc., Solna, Sweden) according to ATS guide-
lines.22 This chemiluminescence gas analyzer is sensitive to
measure NO at concentrations from 1.5 ppb to 200 ppb with
a deviation from mean values of 2.5 ppb < 50 ppb or 5%
of the measured value >50 ppb. We controlled for intra-
subject variability using mean values of three consecutive
measurements.
Laboratory measurements
Blood samples were taken before the challenge. Red and
white blood cell count, concentrations of total IgE, and of
specific IgE (chemiluminescence-immunoassay, Biermann
Inc., Bad Nauheim, Germany) were determined in our
laboratory. Fatty acids in plasma and erythrocyte
membrane (red blood cells; RBCs) were determined at the
NUMICO research laboratory by HPLC/fatty acid methyl
ester (FAME) detection via capillary gas-chromatography.23Table 1 Subjects’ baseline characteristics. Q25 Z first quart
erythrocyte membranes. Inter-group comparison between contr
statistical significant differences unless indicated otherwise.
Controls Asthm
Total
Gender 5 m/14 f 12 m/
Height [cm] 171.1 (0.40) 174.4
Body weight [kg] 63.0 (5.40) 68.2 (
IgE [IU/ml] 77.4 (10.9)* 271.2
Spec. IgE [IU/ml] 0.10 (0.00)** 212.7
IgE Z Immunoglobuline E; spec. IgE Z IgE specific for grass pollen; *Values are expressed in weight percent (wt%) of total fatty
acids and the ratio of omega-3/omega-6 PUFAs.
Statistical analysis
Erythrocyte membrane fatty acids (in % FAME) were cate-
gorized in quartiles according to the distribution in the
total study population. Data analysis was performed using
the software package SPSS for Windows 11.0 (SPSS Inc.,
Chicago, Illinois/USA). All values are expressed as median
values  Standard Errors of Means (SEM). Since data were
not distributed normally, we chose a non-parametric test
(ManeWhitney and Wilcoxon test). Probability
values < 0.05 were considered as significant.
Results
Clinical and laboratory characteristics of the study
population
Our study examined 38 grass pollen allergic asthmatics
(classified according to the Global Initiative for Asthma
(GINA) as “mild intermittent”, GINA I; median age 25.1
years) and 19 healthy controls (median age 22.5 years;
Table 1). When stratifying for levels of PUFA in erythrocyte
membranes and limiting the analysis to low (25th quartile;
Q25) vs. high (75th quartile; Q75) ratios of omega-3 (n-3) to
omega-6 (n-6) PUFAs, analysis encompassed 16 asthmatics.
There was a trend of a more frequent sea fish consumption
in Q75 subjects compared to the Q25 group (p Z 0.07).
PUFA concentrations in plasma and erythrocyte
membranes
Ratios of n-3/n-6 PUFA were significantly lower in asth-
matics (0.29, SEM 0.063) than in healthy controls (0.33, SEM
0.038; p Z 0.038; see Fig. 1).
Bronchial hyperreactivity to metacholine and
single-dose grass pollen challenge
The procedures were well tolerated by all subjects. There
was a trend of a higher bronchial hyperreactivity to meta-
choline in Q25 asthmatics (median PD20 0.15, SEM 0.08)
compared to Q75 asthmatics (median 0.27, SEM 0.03,ile and Q75 Z forth quartile of n-3/n-6-ratio of PUFAs in
ols and asthmatics or Q25 and Q75 asthmatics revealed no
atic
Q25 Q75
26 f 1 m/7 f 2 m/6 f
(0.28) 173.0 (1.18) 170.0 (1.64)
4.10) 73.8 (2.38) 61.5 (1.60)
(9.63)* 147.5 (17.6) 353.5 (83.5)
(8.26)** 169.6 (27.6) 147.4 (43.1)
p Z 0.04; **p Z 0.005.
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Figure 1 Ratio of n-3/n-6 PUFA levels in erythrocyte
membranes in allergic asthmatics compared to healthy
controls.
1796 R. Kitz et al.p Z 0.37). This was confirmed by the results from the
specific bronchial challenge with grass pollen: FEV1
decrease in Q25 asthmatics 20.9 (SEM 2.11) vs. 19.3 (SEM
2.18) in Q75 asthmatics; p Z 0.84.
Exhaled nitric oxide (eNO)
Levels of eNO were significantly higher (p Z 0.040) in Q25
asthmatics (median 35.4, SEM 5.95) than in Q75 asthmatics
(13.0, SEM 2.09; Fig. 2).
Discussion
Epidemiological studies support the thesis of a positive
impact of n-3 PUFAs on atopic and asthmatic airway
disease. A case-control study of the dietary intakes of
Spanish adult subjects with asthma (n Z 54) showed
a positive correlation of n-3 fatty acid intake with FEV1.
24 In
a nested case-control study, Murray and coworkers exam-
ined 3e5 year old children with recurrent wheeze. Young
sensitized wheezy children had a significantly higher total
polyunsaturated fat intake compared to non-sensitized1 , 0 
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Figure 2 Markers of bronchial inflammation depending on
LC-PUFA in erythrocyte membranes of asthmatics. LC-PUFA-
long-chain polyunsaturated fatty acids; DeNO Z change of
exhaled nitric oxide; PD20 Z dosage of grass pollen challenge
causing a 20% decrease of FEV1; D FEV1 Z change of forced
expiratory volume within 1 s.children as calculated from patients nutrition diaries.25
A cross sectional population-based study German study
examined 568 adults, detecting a high content of n-3 fatty
acids in erythrocyte membranes or in the diet as associated
with a decreased risk of allergic sensitization and allergic
rhinitis.26 A recent study on 2112 North-American and
Canadian students detected low dietary n-3 fatty acid
intake as associated with lower pulmonary function and
increased respiratory symptoms.27
Thus, an intervention supplementing food with n-3
PUFAs appears reasonable. In a recent study, we examined
allergen-induced airway inflammation developing over two
weeks of repeated low-dose allergen inhalation in sensi-
tized allergic asthmatics.20 Here, bronchial inflammation
was significantly attenuated by five weeks of 0.7 g dietary
n-3 PUFA supplementation, verified by lower levels of
exhaled NO, serum and sputum eosinophils, Eosinophilic
Cationic Protein, and a suppression of the proinflammatory
eicosanoids secreted by leukocytes. This observation sup-
ported previous findings in patients with allergic disease
where n-3 PUFA supplementation reduced the generation of
inflammatory leukotrienes and prostaglandins.13e16,28
Other studies on PUFAs and allergic airway disease
mainly relied on dietary intake data, being subjected to
recall bias. Our approach was to use the fatty acid
composition of erythrocyte membranes, reflecting the
biologically available amount of PUFA in cellular
membranes. With respect to the RBCs life span of 120 days,
these values can be considered as representative for
a relatively long time frame. On the other hand, the fatty
acid analysis of serum phospholipids, which is often per-
formed to assess the alimentary fatty acid intake within the
near past, does hardly represent the biologically relevant
source of precursors for eicosanoid formation, i.e.,
membrane PUFAs.
The potential benefit of n-3 PUFA in the management of
asthma is a matter of debate; a recent meta analysis
review29 encompassing randomized controlled trials
comparing n-3 PUFA supplementation with
placebo12,13,30,31,38 or with n-6 PUFA supplementation15
could not find consistent benefit. The childhood asthma
prevention study group (CAPS)32 reported that a dietary
intervention with approximately 184 mg omega-3 fatty acid
daily significantly reduced cough in atopic infants. Other
authors suggest that omega-3 fatty acid supplementation
reduced arachidonic acid-derived inflammatory mediators,
thereby reducing cough sensitivity in atopic disease.33 The
findings from CAPS could not be confirmed by follow-up
investigations.34 A recent study of Mickleborough et al.35
demonstrated a protective effect of fish oil supplementa-
tion (3 g/d) on exercise-induced bronchoconstriction. In
addition, the same group showed that n-3 PUFA reduced
airway narrowing, medication use, and proinflammatory
mediator generation in non-atopic elite athletes with
exercise-induced bronchoconstriction.36 A comparison of
these studies to our results showed equal reactions to
bronchial stimulation in placebo and Q25 subjects, but only
significant suppression of bronchial reactions in high dose of
EPA supplementation. The underlying mechanism can be
explained in part by a recent in vitro study, where human
alveolar macrophages pretreated with EPA demonstrated
a significantly weaker inflammatory response when
PUFAs and bronchial inflammation in allergic asthma 1797stimulated with lipopolysaccharides.37 These findings
suggest that dietary fish oil supplementation may be
a viable treatment modality and/or adjunct therapy but it
is an ongoing debate, whether higher doses or long-term
supplementation of n-3 PUFA might exhibit more anti-
inflammatory capacity.
A daily intervention of at least 3 g of omega-3 fatty
acids, which is considered a high adult dose, has been used
in several short-term trials.16,27,38 Theoretically, the most
immediate outcome related to n-3 PUFA intake is a change
in tissue levels of the fatty acids. However, the measure-
ment and interpretation of the n-3 PUFA effect is compli-
cated by the tissue distribution, sample sizes, type, and
dose of the n-3 PUFA, and the heterogeneity of asthma
patients.
Nevertheless, even results of studies using low-doses
have been promising. Nagakura et al.13 found that a 10-
month intake of 120 mg n-3 PUFA per day reduced asthma
symptoms scores and bronchial hyperreactivity in children
compared to controls. In another placebo-controlled study
on 60 children from Egypt with moderate persistent
asthma, six weeks of food supplementation with 1 g of
triglyceride oil (containing 30% EPA/DHA) resulted in
a significant improvement of lung functions.39 A lipid
extract of New Zealand green-lipped mussel containing
100 mg n-3 PUFA was recently studied in 46 patients with
atopic asthma. There was a significant decrease in daytime
wheeze and an increase in morning Peak Expiratory Flow in
the lipid extract group compared to the placebo group.40
Also the duration of the dietary manipulation might
explain the discrepancy between epidemiological findings
and the often weak effects of short-term PUFA
supplementation.
A potential pitfall in studies investigating effects of fish oil
on allergies is the phenomenon of reverse causation, i.e.,
allergic subjects might avoid fish intake by themselves due to
food allergies or fear of sensitization. In such a situation, low
PUFA levels in their organisms would be the consequence of
allergic conditions, and not vice versa. Our study’s concept
tried toavoid thisbynotonlydocumentingfishconsumptionof
our patients, but also stratifying for PUFA content of eryth-
rocyte membranes.Conclusions
This study used PUFA distribution in erythrocyte
membranes reflecting dietary intake to assess biologically
available PUFAs at the cellular level and its association with
markers of pulmonary function and inflammation. Our non-
interventional study revealed lower n-3 PUFA levels in
allergic asthmatics than in non-allergic healthy controls.
The increase of exhaled nitric oxide following experimen-
tally induced allergic bronchial inflammation was signifi-
cantly higher in asthmatics with low n-3/n-6 PUFA levels,
implying a mild anti-inflammatory effect of nutritional fish
oil. Overall, regular dietary consumption of fish oil does not
seem sufficient to suppress specific bronchial reactivity. On
the basis of available data, no final recommendation on the
preventive or therapeutic use of PUFAs in allergic diseases
can be given. Further studies with pharmacological doses ofn-3 PUFAs are needed to clarify their role in regulating
allergic asthmatic conditions.
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